Table 2.

Organization to Assess Strategies in Ischemic Syndromes 5: Primary efficacy and safety outcomes at 9 d

Outcomes	Fondaparinux	Enoxaparin	HR (95%CI)	P value
Primary efficacy outcome: Cumulative event rate-Death, MI, refractory ischemia at 9 d
Cumulative event rate	5.80%	5.70%	1.01 (0.90-1.13)	0.007
Primary safety outcome: Major bleeding at 9 d
Major bleeding	2.20%	4.10%	0.52 (0.44-0.61)	P < 0.001

CI: Confidence interval; HR: Hazard ratio.